Cryptosporidium is a microscopic parasite that can cause an unpleasant – and sometimes dangerous – illness called cryptosporidiosis. This nasty bug lives in the intestines of infected humans and animals and is passed out in their poo. It can then …
With the recent emergence of a new group of COVID-19 variants, known collectively as FLiRT, some people are asking about how these new strains compare to other variants. The unofficial nickname was inspired by the names of the mutations in …
Whooping cough cases (also known as the ‘100 day cough’) are rising sharply across England. Between January and March 2024 there have sadly been 5 infant deaths. Vaccination is the best protection.
In this blog post, Catherine Hughes, Founding Director at The Immunisation Foundation of Australia, shares the story of her son Riley Hughes and how their family lost Riley to Whooping cough (pertussis)
Antimicrobial resistance (AMR) occurs when medicines used to fight infections lose their effectiveness because the organisms they target – whether bacteria, fungi, viruses or parasites – have evolved or acquired adaptations to survive. In 2019, AMR was directly responsible for …
Visiting a farm is an enjoyable and educational experience for the whole family, but it carries a risk of infection from animals or the environment. Farm animals may carry germs that can be passed from animals to humans and cause …
In 2017, the Keep Antibiotics Working campaign targeted groups who were most likely to use antibiotics (mothers of children aged 0-16, and people aged over 50), and healthcare professionals dealing with patient care and prescribing. In this blog post, we look at a peer-reviewed study investigating the impact of the campaign.
As we release our Commercial Strategy, I wanted to reflect on the ways in which we partner with industry to drive greater innovations and better health outcomes. One unintended consequence of the response to COVID-19 was the suppression of many …
As we move into spring, protection from any earlier COVID-19 vaccination you may have had will be starting to wane. For those who are more likely to become seriously ill from COVID-19, the NHS offers a free vaccine in the …
Whooping cough, also known as pertussis, is a highly contagious bacterial infection that mainly affects the lungs and airways. Whooping cough is sometimes known as the 100-day cough because of how long it takes to recover from it. What are …
Pharmaceutical company Eli Lilly is urging people not to use its tirzepatide medications Mounjaro and Zepbound for cosmetic weight loss.
They said the drugs are designed for serious diseases and can pose potentially serious health risks to people using them for other purposes.
Experts say the benefits of these drugs outweigh the risks for people with obesity, but that balance may not be true for someone trying to lose a minimal amount of weight.
Officials at Eli Lilly have posted an open letter regarding the use of its FDA-approved tirzepatide medications, Mounjaro and Zepbound, for cosmetic weight loss.
The company stated that it was aware of the practice of these drugs being prescribed or used outside of the parameters of the Food and Drug Administration as well as the use of tirzepatide by compounding pharmacies that mix customized medicines.
“Mounjaro and Zepbound are indicated for the treatment of serious diseases; they are not approved for – and should not be used for – cosmetic weight loss,” the statement reads.
“Products claiming to contain tirzepatide, Mounjaro, or Zepbound that are made and/or distributed by compounding pharmacies have not been reviewed by the FDA or global regulatory agencies for safety, quality, or efficacy; are not FDA-approved or approved by global regulatory agencies like Mounjaro and Zepbound; and may expose patients to potentially serious health risks,” the officials added.
Are Mounjaro and Zepbound safe to take for weight loss?
Mounjaro is available in injectable single-dose pens or vials.
It is recommended for adults with type 2 diabetes to improve blood sugar, but it is meant to be combined with dietary and exercise changes.
There is an FDA warning on Mounjaro about a potential increased risk for thyroid cancer.
In referring to drugs containing tirzepatide, Dr. Dan Azagury, FACS, the chief bariatric surgeon and medical director of Stanford University School of Medicine’s Lifestyle and Weight Management Clinic in California, said using the medications for cosmetic purposes is not recommendable.
Aside from the side effects, he said the drugs can create longer-term problems for people who are trying to lose weight quickly rather than applying dietary and exercise regimens over time for overall health.
“We tell our patients that if they start the drug they should do so being comfortable with the idea of staying on it forever,” Azagury told Healthline. “Because often when you stop there is a rebound effect. In particular, if you stop abruptly. Patients who take this just to lose 5 to 10 pounds and stop will then likely regain 10 to 15 pounds, leading to worse long-term outcomes and a yo-yo effect that is unfavorable. I think educating patients in that way would be beneficial.”
Are Mounjaro and Zepbound different than Ozempic?
Ozempic, along with drugs such as Wegovy, are commonly called GLP-1 drugs, or glucagon-like peptide1 receptor agonists. Tirzepatide drugs are part of the GLP-1 class.
Ozempic is meant to be prescribed to adults with type 2 diabetes to help lower risks of heart disease and manage blood sugar levels, but it is also prescribed off-label — where a drug that’s approved for certain conditions is prescribed for another purpose — for weight loss or weight management.
Azagury said that the use of these type of drugs for purposes other than those approved by the FDA can change the risk factors for people.
“Every drug has side effects and potential risks. When the FDA approves a drug, they weight the benefits vs the risks,” Azagury said. “They issue an indication for use based on that equation. If you’re doing it for cosmetic purposes with no health benefit, then that equation is different and the side effects or risks might outweigh the benefits.”
Dr. Mir Ali, a bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in California, said the statement by Eli Lilly will likely make no difference on how people look for cosmetic weight loss treatments.
“Patients seeking these medications for weight loss will try to obtain them regardless of any warnings,” Ali told Healthline. “These medicines are in short supply because the demand is so high. Many patients who do not meet the manufacturers’ guidelines are seeking these medications for weight loss. These medicines are more effective than diet and exercise alone, so people who do not have significant weight view them as a more convenient solution.”
That type of demand, Azagury said, is also creating problems or people for whom tirzepatide drugs would be beneficial for long-term health.
“It’s unfortunate because this is an expensive drug that is extremely beneficial to patients with obesity and they have difficulty accessing it,” he said. “Its use for cosmetic by people who can afford it is increasing disparities and reducing access for patients who would truly benefit.”